Digital Therapeutics for Insomnia: Clinical Validation for Investors

Software is starting to deliver clinical outcomes that, until now, you could only get from a pill. This shift is being driven by digital therapeutics, but their entire value proposition rests on one thing: hard, peer-reviewed clinical evidence. For any growth-stage healthcare investor, digging into the clinical mechanisms and the trial data behind these products is the only way to separate a real medical innovation from just another wellness app.

The Clinical Science Behind Digital Therapeutics for Insomnia

Digital therapeutics (DTx) for chronic insomnia are a world away from simple meditation apps. These are sophisticated Software as a Medical Device (SaMD) built to deliver cognitive behavioral therapy for insomnia (CBT-I), the gold-standard psychological treatment. The software’s core mechanism is a direct translation of in-person CBT-I, which works by getting patients to identify and change the bad habits and anxious thoughts that fuel their insomnia. This involves proven techniques like sleep restriction, stimulus control, and cognitive restructuring. The digital format makes this therapy scalable and personal, delivering the program through interactive lessons, personalized feedback, and progress tracking. In head-to-head comparisons, traditional CBT-I consistently beats sleeping pills for long-term results, and digital CBT-I (dCBT-I) simply makes this powerful treatment available to a much wider audience. The “how” is all about patient engagement. DCBT-I pulls the user into a structured program that methodically rebuilds healthy sleep patterns while tackling the root cognitive issues, using the digital interface to give instant feedback, reinforce good behavior, and adapt the plan based on the user’s own data.

Clinical Trial Data: Pear Therapeutics’ Somryst and Big Health’s Sleepio

For any investor, the real test for a digital therapeutic is its clinical validation. You need to see strong randomized controlled trials (RCTs) published in serious medical journals. Two of the biggest players in the dCBT-I space, Somryst (originally from Pear Therapeutics) and Sleepio (from Big Health), show what this looks like in practice. Pear Therapeutics filed for Chapter 11 bankruptcy in April 2023, and Nox Health acquired its assets, including Somryst, in May 2023. Somryst made history as the first FDA De Novo Classified digital therapeutic for chronic insomnia back in March 2020. That clearance was built on data from two major RCTs with over 1,400 adults. The results were clear: significant drops in insomnia severity, how long it took to fall asleep, and time spent awake at night. For example, one key study in JAMA Psychiatry found a major reduction in insomnia severity scores for Somryst users versus the control group JAMA study on Somryst efficacy. In that trial, people fell asleep 45% faster and spent 52% less time lying awake at night. The trial designs were powered correctly with large enough sample sizes to produce statistically meaningful results, and the adherence data gave a clear picture of how well patients stuck with the program. Somryst is now available through employer health plans and health systems. Big Health’s Sleepio tells a similar story, backed by a mountain of evidence. SleepioRx, its prescription version, got FDA clearance in August 2024 after being tested in over 25 clinical trials, including 18 RCTs. Its effectiveness in improving sleep has been shown again and again in high-impact journals. One frequently cited JAMA study found that Sleepio users got results comparable to face-to-face CBT-I JAMA study on Sleepio effectiveness. With SleepioRx, users saw the time it took to fall asleep drop by up to 55% and spent 63% less time awake during the night. What’s more, studies show patients stick with Sleepio. The research shows sustained engagement that leads to durable benefits, with up to 76% of patients hitting a healthy sleep status and maintaining those improvements for as long as three years. Getting FDA clearance is a huge differentiator for these platforms, it shows their approach is both novel and clinically meaningful, setting a very high bar for anyone else trying to enter this market.

Why RCT-Backed Efficacy is Essential for Digital Therapeutic Survival

For a growth-stage healthcare investor, strong RCT-backed efficacy isn’t just a nice-to-have. It’s an absolute requirement for a digital therapeutic to even exist. The market is getting crowded. The line between a wellness app and a clinically validated medical device has to be sharp and clear. A company that has done the hard work of generating high-quality clinical data, especially with publications in journals like JAMA, has fundamentally de-risked the investment by proving its commitment to outcomes and regulation. Without that bedrock of evidence, a DTx is dead in the water when it comes to reimbursement and provider adoption. Why would payers cover it? They are putting every digital health solution under a microscope, demanding proof that it works and is cost-effective. A solid clinical data package is what gets you CPT Codes and opens the door to coverage. In fact, in November 2024, CMS approved new reimbursement codes (G0522, G0553, G05524) for digital mental health tools like SleepioRx and Somryst, and the CPT code 98978 for remote monitoring of CBT was also finalized. A lack of evidence is also how an AI-native company becomes a “zombie”, it raises a seed round on a good idea but can’t get follow-on funding because it has no proof of clinical traction. The quality of the clinical evidence is a direct commercial predictor. Companies that can show real-world efficacy with published results are the ones set up for market success and long-term survival, because that rigor also points to a mature Quality Management System (QMS) and good practices (like GMLP) that regulators and investors demand during due diligence.

Methodology and Source Note

This analysis is based on a review of the randomized controlled trials for digital cognitive behavioral therapy for insomnia. We focused on studies published in top-tier medical journals, especially the JAMA network, and the evidence packages that supported FDA clearances. We verified data points like clinical trial sample sizes, sleep latency improvement rates, and long-term adherence stats by going to the primary sources wherever possible. The point here is to give growth-stage healthcare investors a high-level, evidence-based view of what actually matters when evaluating companies in the digital therapeutics sector. You can look up cleared devices yourself in the FDA database for cleared digital therapeutics.